Stocks › ANAB

ANAPTYSBIO, INC

ANAB·Nasdaq·United States United States·USD
$46.63
-0.77 (-1.62%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ANAB
ANAPTYSBIO, INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ANABS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ANAB by members of U.S. Congress · 0 on record

No congressional trades in ANAB on record.

Whale Activity

Position changes in ANAB reported for 2026-09-30 by 261 institutional filers
Increased: 88New: 45Held: 25Decreased: 60Closed: 33No prior filing: 10
  • Increased88
  • New45
  • Held25
  • Decreased60
  • Closed33
  • No prior filing10
FilerSharesValueChange
EcoR1 Capital, LLC7.9M$396.1Mheld
BlackRock, Inc.1.9M$95.1Mincreased
TANG CAPITAL MANAGEMENT LLC1.5M$74.1Mincreased
STATE STREET CORP1.1M$57.6Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC909.9K$45.7Mincreased
GOLDMAN SACHS GROUP INC850.3K$42.7Mincreased
Sanofi821.9K$41.3Mheld
D. E. Shaw & Co., Inc.819.6K$41.2Mincreased
MILLENNIUM MANAGEMENT LLC784.6K$39.4Mdecreased
683 Capital Management, LLC740.0K$37.2Mincreased
CITADEL ADVISORS LLC650.6K$32.7Mincreased
GEODE CAPITAL MANAGEMENT, LLC639.7K$32.2Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ANAB insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: 6,6462025 Q12025 Q2: -3,0152025 Q22025 Q3: -39.4K2025 Q32025 Q4: -63.8K2025 Q42026 Q1: -130.8K2026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 369.6K2026 Q4

Recent Insider Transactions

324 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
EcoR1 Capital, LLC / NODELMAN OLEGDirector · Director Purchase +138.1K $46.54 $6.4M Nov 18, 2026 Form 4 ↗
EcoR1 Capital, LLC / NODELMAN OLEGDirector · Director Purchase +152.4K $45.66 $7.0M Nov 17, 2026 Form 4 ↗
EcoR1 Capital, LLC / NODELMAN OLEGDirector · Director Purchase +84.1K $45.66 $3.8M Nov 16, 2026 Form 4 ↗
RENTON HOLLINGSDirector · Director Sale −5,000 $49.87 $249K Oct 1, 2026 Form 4 ↗
Orwin John ADirector Option exercise +1,300 $0.00 $0 Sep 15, 2026 Form 4 ↗
Schmid John P.Director Option exercise +6,030 $0.00 $0 Jun 15, 2026 Form 4 ↗
Orwin John ADirector Option exercise +6,030 $0.00 $0 Jun 15, 2026 Form 4 ↗
RENTON HOLLINGSDirector Option exercise +6,030 $0.00 $0 Jun 15, 2026 Form 4 ↗
Schmid John P.Director Sale −522 $57.40 $30K Mar 30, 2026 Form 4 ↗
Schmid John P.Director Sale −7,527 $56.70 $427K Mar 30, 2026 Form 4 ↗
Schmid John P.Director Sale −12.6K $55.71 $702K Mar 30, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −100 $65.99 $7K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −3,038 $65.20 $198K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −3,155 $64.19 $203K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −2,592 $63.35 $164K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −1,012 $62.15 $63K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −550 $60.63 $33K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −490 $59.62 $29K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −3,662 $58.62 $215K Mar 27, 2026 Form 4 ↗
Faga DanielPresident, CEO · Director Sale −2,570 $57.91 $149K Mar 27, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ANAB · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
786.6K$53.1M0.49%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
648.1K$43.7M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
514.9K$34.8M0.04%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
237.0K$16.0M0.02%Jun 30, 2026
Nuveen Quant Small Cap Equity Fund
TIAA-CREF Funds
263.8K$14.1M0.35%Jul 31, 2026
iShares Biotechnology ETF
iShares Trust
193.5K$13.1M0.14%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
185.5K$12.5M0.08%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
215.9K$11.5M0.03%Jul 31, 2026
Federated Hermes Kaufmann Small Cap Fund
Federated Hermes Equity Funds
210.0K$11.2M0.39%Jul 31, 2026
Victory Science & Technology Fund
Victory Portfolios III
187.9K$10.0M0.67%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list ANAB's shares (CUSIP 032724106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • EcoR1 Capital Fund Qualified, L.P.SCHEDULE 13D/A · activist (13D) · 7.6M shares25.7%
    Nov 18, 2026 · ↗
  • Oleg NodelmanSCHEDULE 13D/A · activist (13D) · 8.3M shares27.8%
    Nov 18, 2026 · ↗
  • EcoR1 Capital, LLCSCHEDULE 13D/A · activist (13D) · 8.3M shares27.8%
    Nov 18, 2026 · ↗
  • Alex SilversteinSCHEDULE 13G/A · passive (13G) · 924.6K shares3.1%
    Nov 16, 2026 · ↗
  • Sirenia Capital Management LPSCHEDULE 13G/A · passive (13G) · 924.6K shares3.1%
    Nov 16, 2026 · ↗
  • Alex SilversteinSCHEDULE 13G/A · passive (13G) · 1.5M shares5.0%
    Aug 14, 2026 · ↗
  • Sirenia Capital Management LPSCHEDULE 13G/A · passive (13G) · 1.5M shares5.0%
    Aug 14, 2026 · ↗
  • Steven A. CohenSCHEDULE 13G/A · passive (13G) · 55.3K shares0.2%
    May 15, 2026 · ↗
  • Point72 Capital Advisors, Inc.SCHEDULE 13G/A · passive (13G) · 55.3K shares0.2%
    May 15, 2026 · ↗
  • Point72 Asset Management, L.P.SCHEDULE 13G/A · passive (13G) · 55.3K shares0.2%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming ANAPTYSBIO, INC as client

No lobbying filings found naming ANAPTYSBIO, INC as the client.

Government Contracts

Federal awards to ANAPTYSBIO, INC · USAspending

No federal contract awards found for ANAPTYSBIO, INC.

U.S. Patents

Recent USPTO applications naming ANAPTYSBIO, INC

No USPTO patent applications found for ANAPTYSBIO, INC.

Annual Financials

From ANAB's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$234.6M$91.3M$17.2M$10.3M$63.2M
Operating income$47.9M-$114.9M-$164.4M-$115.2M-$56.8M
Net income-$13.2M-$145.2M-$163.6M-$128.7M-$57.8M
Diluted EPS-$0.46-$5.12-$6.08-$4.57-$2.11
Operating cash flow$19.7M-$135.3M-$120.8M-$73.6M-$45.9M
Cash and equivalents$238.2M$123.1M$36.0M$71.3M$495.7M
Total assets$364.4M$483.8M$452.4M$610.4M$643.1M
Shareholders' equity$37.2M$70.9M$88.1M$262.1M$356.4M

As ANAPTYSBIO, INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 3, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 3-for-2Stock splitApr 20, 2026

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
    EDGAR ↗
  • 8-K · Items 9.01Sep 21, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 9.01Shareholder voteAug 11, 2026
    EDGAR ↗
  • 8-K · Items 7.01Reg FD disclosureJul 30, 2026
    EDGAR ↗
  • 8-K · Items 1.01Material agreementJun 22, 2026
    EDGAR ↗
  • 8-K · Items 7.01Reg FD disclosureMay 29, 2026
    EDGAR ↗
  • 8-K · Items 5.03Bylaw amendmentMay 21, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeMay 11, 2026
    EDGAR ↗

About ANAPTYSBIO, INC

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
Former namesANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC